NICE rejects Alzheimer’s disease drugs for third time

The National Institute for Health and Clinical Excellence (NICE) has again rejected the use of Alzheimer’s disease (AD) treatments donanemab (Kisunla; Eli Lilly) and lecanemab (Leqembi; Eisai). In final draft guidance, published on 19 June 2025, NICE ruled against the AD treatments for use in the NHS in England and Wales for the third time, […]

Publication Details

Journal: Pharmaceutical journal/The pharmaceutical journal
Published: 2025-01-01
DOI: https://doi.org/10.1211/pj.2025.1.361314
Primary Topic: Science, Research, and Medicine
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

NICE rejects Alzheimer’s disease drugs for third time

Jan 1, 2025

Pharmaceutical journal/The pharmaceutical journal

Science, Research, and Medicine

article

NICE rejects Alzheimer’s disease drugs for third time

January 1, 2025article en

Abstract

Pharmaceutical journal/The pharmaceutical journal

Openalex Percentile: Top 80%

Science, Research, and Medicine

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

NICE rejects Alzheimer’s disease drugs for third time · Pharmaceutical journal/The pharmaceutical journal (2025) | TGRS Research Map | TGRS